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ABSTRACT
Plasma cell leukemia (PCL) is a rare form of plasma cell dyscrasia. Between 2% and 4% of malignant PCD cases are PCL. The 
presentation may be primary, de novo, or secondary, evolving from an existing case of myeloma as part of the terminal phase of the 
disease. The median age of patients is 50-60 years with an equal incidence in males and females. Here, we report a case of primary 
PCL, presenting at the age of 62 years.
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The first case of plasma cell leukemia (PCL) was recognized by Gluzinski and Reichentein [1]. The presentation may be primary, de novo, or secondary, evolving from an existing 
case of myeloma as part of the terminal phase of the disease. 
About 60% to 70% of cases are primary [2]. The incidence of 
primary PCL is very rare and reported to occur in less than one in 
a million [3]. PCL patients usually have accompanying anemia, 
hypercalcemia, renal insufficiency and organomegaly. Two types 
of PCL are seen: secretory and non-secretory. No M-protein is 
detected in the non-secretory type of PCL. PCL is more frequent 
in the light chain only, IgE and IgD myeloma and is less frequently 
seen in IgG or IgA myeloma. 
By definition, there are more than 20% plasma cells in the 
peripheral blood and an absolute plasma cell count of more 
than 2x109/L [4,5]. PCL has a relatively poor prognosis, due 
to its very aggressive nature involving extramedullary organs, 
lytic bone lesions and bone marrow failure. Treatment includes 
immunomodulators, proteasome inhibitors, and autologous stem 
cell transplantation. Outcomes are not promising, however, 
even after treatment; median survival after chemotherapy and 
transplant is not more than three years [6]. As prognosis is very 
poor, it is very important to recognize this entity sufficiently early 
so that one can offer combination chemotherapy at the earliest 
which can prolong survival. 
CASE REPORT
A 62-years-old female presented to the emergency with 
complaints of weakness, easy fatigability, back pain, and high-
grade fever since two months. She did not have any significant 
past and family history. On examination, the vitals were stable. 
The patient was investigated. 
A complete hemogram showed haemoglobin of 7.7 g/dl, total 
white blood cell count of 8000/mm3 and a platelet count of 50,000/
mm3. Peripheral smear showed 26% of immature and mature 
plasma cells (absolute count=2,080/mm3) and numerous reactive 
lymphocytes. Rouleaux formation was also seen (Fig. 1).Renal 
function tests were deranged with blood urea levels of 315mg/dl 
and serum creatinine levels of 7.5 mg/dl, and serum uric acid levels 
of 10mg/dl. Ultrasound revealed hepatosplenomegaly. Urine was 
negative for Bence Jones Proteins. Serum electrophoresis was 
done. High-resolution serum protein electrophoresis revealed 
the presence of a densely staining monoclonal gammopathy (‘M’ 
spike) in the gamma globulin region. A bone marrow aspiration 
was then done. Bone marrow smears revealed diffuse involvement 
of bone marrow by mainly mature plasma cells (86%) and few 
immature plasma cells (9%) (Fig. 2).
Based on the findings of peripheral smear andbone marrow,the 
patient was diagnosed to have pPCL. He was given supportive 
care and bortezomib based chemotherapy was initiated. However, 
the patient was lost to follow-up.
Figure1: Peripheral smear showing Rouleaux formation and 
plasma cells (Leishman stain, 400X).
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DISCUSSION
Plasma cell leukemia is a rare and aggressive variant of plasma 
cell dyscrasia, accounting for only 2-4% of all plasma cell 
dyscrasias [7]. By definition, there should be >20% plasma cells 
in the peripheral blood or an absolute plasma cell count >2×109 
/L.The median age of patients is 50-60 years with an equal 
incidence in males and females. Phenotypically, they originate 
from the proliferation of plasma cells expressing CD38 [8] .
Clinical presentation of Plasma cell leukemia is more 
aggressive than that of multiple myeloma with a higher presenting 
tumour burden and higher frequencies of extramedullary 
involvement, anemia, thrombocytopenia, hypercalcemia, renal 
impairment, increased levels of serum lactate dehydrogenase, 
beta-2 microglobulin and plasma cell proliferative activity [9]. 
Though the clinical and laboratory features of primary and 
secondary plasma cell leukemia are similar, the response to 
therapy and overall survival in primary plasma cell leukemia goes 
from poor to worse.
Response to treatment of PCL is poor. Median survival is less 
than 1 year.Since the prognosis is so poor, intensification of high 
dose chemotherapy followed by allogeneic/autologous stem cell 
rescue should be tried [10]. The most important prognostic factor 
in pPCL remains response to treatment as patients presenting 
with the disease that is resistant to initial therapy have the poorest 
outcome [11]. 
The current treatment plan follows the steps involved in the 
management of multiple myeloma. Induction therapy includes 
various bortezomib-based regimens such as VDT-PACE 
(bortezomib, dexamethasone, thalidomide, cisplatin, adriamycin, 
cyclophosphamide, and etoposide), VDT (bortezomib, 
thalidomide, and dexamethasone), VAD (bortezomib, doxorubicin, 
and dexamethasone),  VRD (bortezomib, lenalidomide, 
and dexamethasone) or VMP (bortezomib, melphalan, and 
prednisone).
Although the best induction regimen for PCL is not known. 
Recently, lenalidomide and bortezomib-based regimens have 
demonstrated activity and are more widely used. In a multicenter 
retrospective study involving 42 patients with pPCL, bortezomib-
based therapies were associated with 69% response rates, 
1–3-month median survival time [12]. Although there is great 
variability in treatment plans, typically individuals <65 years in 
good performance status are treated with aggressive induction 
therapies such as VDT-PACE. 
CONCLUSION
Plasma cell leukemia is a rare and aggressive form of leukemia 
with poor prognosis. As survival rates are low, such information 
is necessary to ensure PCL cases can be diagnosed early and 
appropriate treatment regimens initiated.
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Figure 2: (a) Bone marrow aspirate showing plasma cells 
(Leishman stain,400X); (b) bone marrow biopsy showing sheets of 
plasma cells (H& E stain, 400X).
